Abstract
The identification of prognostic and predictive biomarkers in oncological pathology is a desideratum of translational research in cancer. The neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR) were considered suggestive to characterize both cell-mediated immune status and inflammation in cancer, thus being potential biomarkers. Due to the high rate of therapeutic failure even in the case of a treatment with curative potential, head and neck cancers are a priority in the research of potential biomarkers that allow a stratification of risk groups in order to adapt the therapy. The aim of the study is the dynamic evaluation of NLR and nadir PLR and during chemotherapy cycles for patients with multimodal, nonsurgically treated head and neck cancers. The mean NLR and PLR values vary during treatment, but the mean nadir value is not significantly different from the mean NLR and PLR values before the last cycle of chemotherapy. If there is solid evidence regarding the role of NLR nadir as a biomarker, the evaluation of NLR and PLR dynamics requires further research to confirm the possibility of being validated as a prognostic or predictive biomarker of response to chemotherapy and radiotherapy in head and neck squamous cell carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.